October 26, 2021 7:50am

Increased volume, patience with LPS (loss-per-share) earnings without electronic sell trading algorithms

Pre-open indications: 7 SELLs into Strength and with 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.34% (+120 points), S&P futures are UP +0.42% (+19 point) and NASDAQ futures are UP +0.61% (+95 point)

 

U.S. stock futures rose in morning trading Tuesday pre-open,

European stocks were also higher

Asia-Pacific stocks were mixed as Japan and Australia rose while Mainland China closed lower along with Hong Kong.

 

Henry’omics:

Record highs on Monday as the Dow gained +0.18%, the S&P 500 gained +0.47% while the Nasdaq - the outperformer, rose +0.9% and is about +1.1% from its record high.

I usually say BYE after record highs but, with “our” universe and sector earnings coming this week and next – I say RUN …

 

If you didn’t remember what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

 

Q4: October, 7 positive and 10 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed flat at $3.05 with 609 shares traded after Friday’s -$0.156 with 516 shares traded, Thursday’s -$0.095 with 265 shares traded, Wednesday’s +$0.30 with 8,356 shares traded and last Tuesday’s flat with 1,488 shares traded.

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
  • What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

 

Maintaining SELL into Strength:

bluebird bio (BLUE) closed up +$0.43 after Friday’s +$0.41 to $20.80 and Thursday’s -$0.59 with a negative -$0.03 or -0.14% pre-open indication.

 

Sell into Strength:

BioLife Solutions (BLFS) closed up +$2.28 to $45.28 after Friday’s +$0.01 and Thursday’s +$0.54, Wednesday’s +$0.38 and last Tuesday’s +$0.46 with NO pre-open indication.

Editas Medicine (EDIT) closed up +$0.39 to $38.21 after Friday’s -$0.31 with a positive +$0.30 or +0.79% pre-open indication.

Intellia therapeutics (NTLA) closed up +$2.02 to $133.55 after Friday’s -$2.68, Thursday’s +$5.07, Wednesday’s -$3.54 and last Tuesday’s +$1.85 with a positive +0.45 or +0.34% pre-open indication.

Sage Therapeutics (SAGE) closed up +$0.01 to $41.43 after Friday’s +$0.19 to $41.42, Thursday’s +$0.33 to $41.23, Wednesday’s +$0.61 to $40.90 with NO aftermarket indication,

Ultragenyx Pharmaceuticals (RARE) closed up +$1.47 to $79.69 after Thursday’s +$1.44 and Wednesday’s -$1.08) with a positive +$1.31 or +1.64% pre-open indication.

uniQure NV (QURE) closed up +$0.90 to $29.36 after Thursday’s -$0.23 with NO pre-open indication after reporting a net loss of -$36.5 M or -$0.79 per shares, a +$200 K upload of revenue from Q2, $578.5 M in cash and a runway until 1H/24.

 

The BOTTOM LINE: Reiterating, “Don't let earnings week take advantage of you.”

Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.

It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

The stem, cell and gene therapy earnings with Alnylam Pharmaceuticals on 10/28, Sage Therapeutics (SAGE) on 11/2, Editas medicine (EDIT) on 11/8, Vericel (VCEL) on 11/9, Athersys ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.